This page shows the latest Dengvaxia news and features for those working in and with pharma, biotech and healthcare.
such as dengue fever vaccine Dengvaxia to deliver revenues as expected.
vaccine Dengvaxia last year, as well as lumpy orders for its meningitis vaccine Menactra and overall static sales of paediatric combination shots. ... Sanofi’s vaccines sales grew 8.3% overall last year, but growth shrank to 1.2% in the fourth-quarter,
stage pipeline setbacks, including big problems for new dengue fever vaccine Dengvaxia.
It’s also suffered a couple of major setbacks in its pipeline, including the failure of its dengue vaccine Dengvaxia which had been tipped as a blockbuster but is now looking ... In the Philippines - one of the only countries to use the vaccine
And the annual R&D day comes at a difficult couple of weeks for the company, in the wake of major problems for its dengue fever vaccine Dengvaxia - once tipped as
Prospects for Sanofi’s dengue fever vaccine Dengvaxia look increasingly dim after it confirmed a long-debated safety issue with the product. ... That cuts down the eligible patient population for Dengvaxia by some margin, as it is less likely to be
More from news
Approximately 3 fully matching, plus 10 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...